Compare PFSI & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFSI | BSX |
|---|---|---|
| Founded | 2008 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 68.0B |
| IPO Year | 2018 | 2010 |
| Metric | PFSI | BSX |
|---|---|---|
| Price | $61.95 | $43.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 31 |
| Target Price | ★ $90.57 | $61.00 |
| AVG Volume (30 Days) | 453.6K | ★ 17.4M |
| Earning Date | 10-20-2026 | 10-28-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ 59.25 | 55.20 |
| EPS | ★ 1.94 | 1.51 |
| Revenue | $984,629,000.00 | ★ $9,076,000,000.00 |
| Revenue This Year | N/A | $5.95 |
| Revenue Next Year | $25.92 | $4.60 |
| P/E Ratio | $32.82 | ★ $28.81 |
| Revenue Growth | 3.05 | ★ 12.49 |
| 52 Week Low | $63.03 | $42.20 |
| 52 Week High | $160.36 | $105.65 |
| Indicator | PFSI | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 22.34 | 40.37 |
| Support Level | N/A | $42.49 |
| Resistance Level | $87.46 | $46.06 |
| Average True Range (ATR) | 1.59 | 1.02 |
| MACD | -0.27 | 0.06 |
| Stochastic Oscillator | 3.79 | 27.48 |
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform mainly focused on the production and servicing of U.S. residential mortgage loans. The firm is also engaged in managing investments related to the U.S. mortgage market and provides products and services that leverage technologies to support customers. The company operates through two reportable operating segments: production and servicing. The production segment performs loan origination, acquisition, and sale activities, while the servicing segment performs servicing and subservicing of loans, early buyout transactions, and servicing of loans sourced and managed for PMT. The majority of revenue comes from the production segment.
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.